Country: Australia
Bahasa: Inggeris
Sumber: Department of Health (Therapeutic Goods Administration)
pemetrexed disodium
Dr Reddys Laboratories Australia Pty Ltd
pemetrexed disodium
PEMETREXED-DRLA v2 1 PEMETREXED-DRLA _Contains the active ingredient pemetrexed disodium _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET READ THIS LEAFLET CAREFULLY BEFORE TAKING YOUR MEDICINE. This leaflet answers some of the common questions about pemetrexed. It does not contain all the information that is known about pemetrexed. It does not take the place of talking to your doctor and pharmacist. All medicines have risks and benefits. Your doctor will have weighed the risks of you taking this medicine against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT THIS MEDICINE IS USED FOR The name of your medicine is Pemetrexed-DRLA. It contains the active ingredient pemetrexed disodium. Pemetrexed is used to treat: mesothelioma, a rare cancer of the lungs often related to exposure to asbestos non-small cell lung cancer, a type of lung cancer. It belongs to a group of medicines called cytotoxic or antineoplastic agents. They may also be called chemotherapy medicines. It affects enzymes within cancer cells to kill cancer cells or prevent them growing and multiplying. Your doctor may have prescribed it for another purpose. ASK YOUR DOCTOR OR PHARMACIST IF YOU HAVE ANY QUESTIONS ABOUT WHY IT HAS BEEN PRESCRIBED FOR YOU. This medicine is available only with a doctor's prescription. Pemetrexed may be used in combination with other chemotherapy drugs. BEFORE YOU ARE GIVEN THIS MEDICINE _WHEN YOU MUST NOT BE GIVEN _ _IT _ DO NOT TAKE THIS MEDICINE IF YOU ARE ALLERGIC TO ANY MEDICINE CONTAINING PEMETREXED DISODIUM OR ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET. Some symptoms of an allergic reaction include skin rash, itching, shortness of breath or swelling of the face, lips or tongue, which may cause difficulty in swallowing or breathing. IF YOU ARE NOT SURE WHETHER YOU SHOULD BE GIVEN THIS MEDICINE, TALK TO YOUR DOCTOR. _BEFORE YOU ARE GIVEN Baca dokumen lengkap
Product Information Pemetrexed-DRLA PI V3 1 PEMETREXED-DRLA POWDER FOR INJECTION NAME OF THE MEDICINE Pemetrexed disodium Chemical Name: L-glutamic acid, _N_-[4-[2-(2-amino-4,7-dihydro-4-oxo-1_H_-pyrrolo[2,3-_d_]pyrimidin-5- yl)ethyl]benzoyl]-, disodium salt. Structural Formula: Molecular formula: C 20 H 19 N 5 Na 2 O 6 Molecular weight: 471.4 CAS Number: 150399-23-8. DESCRIPTION Pemetrexed disodium is a white to cream color powder with or without green/yellow tinge. Pemetrexed-DRLA powder for injection is supplied as a sterile lyophilised powder for intravenous infusion available in single dose vials. The product is a white to either light-yellow or green-yellow lyophilized powder. Pemetrexed-DRLA is supplied in 500 mg and 100 mg vials. Each 500 mg vial contains pemetrexed disodium equivalent to 500 mg pemetrexed and 500 mg of mannitol. Each 100 mg vial contains pemetrexed disodium equivalent to 100 mg pemetrexed and 106 mg of mannitol. Hydrochloric acid and/or sodium hydroxide may have been added to adjust pH. PHARMACOLOGY PHARMACODYNAMIC PROPERTIES Pemetrexed is an antifolate antineoplastic agent_. In vitro _studies have shown that pemetrexed behaves as a multitargeted antifolate by inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT), which are key folate-dependent enzymes for the de novo biosynthesis of thymidine and purine nucleotides that are essential for cell replication. Both the reduced folate carrier and membrane folate binding protein transport systems appear to be involved in transport of pemetrexed into cells. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folyl polyglutamate synthetase. The polyglutamate forms are even more potent inhibitors of TS and GARFT than pemetrexed. Polyglutamation is a time- and concentration-dependent process that occurs in tumour cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have a longer intracellular half-life than the parent drug, re Baca dokumen lengkap